Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lamivudine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Lamivudine | DRUG | - |
| Telbivudine | DRUG | - |
Inclusion Criteria: * Documented clinical history compatible with chronic hepatitis B * Patient has compensated liver disease * Patient has received previous treatment with lamivudine for a duration of at least 3 months and not more than 12 months Other protocol-defined inclusion criteria may appl...
Lamivudine is an investigational small molecule being studied for the treatment of Chronic Hepatitis B. It is currently in Phase 3 clinical development. The drug is being evaluated in a completed Phase 3 trial that enrolled 240 adults with Chronic Hepatitis B.
Lamivudine is being developed by Novartis AG, which trades under the ticker NVS. The company is conducting clinical research on this small molecule for Chronic Hepatitis B, an infectious disease indication.
Lamivudine is in Phase 3 clinical development for Chronic Hepatitis B. It is an investigational drug, meaning it has not been approved by regulatory authorities. One Phase 3 trial has been completed, with 240 participants enrolled.
Lamivudine has one completed Phase 3 clinical trial registered under NCT00132652. The study, titled "Switching Therapy From Lamivudine to Telbivudine Versus Continued Lamivudine in Adults With Chronic Hepatitis B," enrolled 240 participants across multiple countries including the United States, Canada, China, and the United Kingdom.
No, Lamivudine is not the same as telbivudine. They are separate drugs. A clinical trial (NCT00132652) compared switching therapy from Lamivudine to telbivudine versus continuing Lamivudine in adults with Chronic Hepatitis B, indicating they are distinct treatments.